Arrowstreet Capital
BIOA

Arrowstreet Capital’s BioAge Labs BIOA Stock Holding History

Arrowstreet Capital’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Buy
+87,881
New +$1.69M ﹤0.01% 1456

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Arrowstreet Capital's BIOA Position: Q1 2026 in Review

Arrowstreet Capital opened a new position in BioAge Labs (BIOA) in Q1 2026: 87,881 shares worth $1.54M. The stake represents ﹤0.01% of the portfolio and ranks #1456 among its holdings.

144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Arrowstreet Capital held 87,881 shares of BioAge Labs worth $1.54M as of Q1 2026.
  • BioAge Labs was a new Arrowstreet Capital position in Q1 2026.
  • BioAge Labs made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1456 holding.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.